Melanotan II
Women's HealthFor women considering Melanotan II, the framework spans three life stages: reproductive, perimenopausal, and postmenopausal. Each carries distinct hormonal context and distinct monitoring requirements. The cyclic α-MSH analogue with MC4R activity — tanning effects plus the sexual-response effects that led to its derivative bremelanotide (PT-141). The ~30 min pharmacokinetic profile shapes how the compound is felt across follicular versus luteal phases in pre-menopausal users and how it integrates with HRT in older cohorts.
Key Takeaways
Female-physiology lens: Melanotan II response varies across follicular and luteal phases for premenopausal users; integrates with HRT in perimenopause and postmenopause. Mechanism: Non-selective melanocortin receptor agonist (MC1, MC3, MC4, MC5). Female monitoring: cycle-day-appropriate estradiol, progesterone, FSH, LH, prolactin, TSH, bone markers; pregnancy contraindication is default. Female dose: 0.25-0.5 mg daily during loading, then 1-2x weekly via subq/intranasal; cycle-phase tracking for 1-2 cycles. Female-physiology stack partners: Oxytocin, Kisspeptin, GHK-Cu.
Non-selective melanocortin receptor agonist (MC1, MC3, MC4, MC5). MC1R drives pigmentation; MC4R drives appetite suppression and sexual response; MC3R/5R contribute to energy expenditure and sebaceous secretion. Cyclic structure resists enzymatic degradation. For women's-health applications, the mechanism is evaluated against cyclical context, fertility implications, bone remodelling, and cardiovascular tone. Melanotan II's contribution to each varies; the subsections below work through these in turn.
Bone density and cardiovascular signalling
Two areas where female physiology diverges sharply post-menopause are bone remodelling and cardiovascular tone. Melanotan II's effect on these systems is one of the underweighted but practically important considerations for women using peptides through the menopausal transition. Bone-marker labs (CTX, P1NP) and cardiovascular indices (lipids, blood pressure, hsCRP) provide a tractable monitoring framework.
Cyclical and hormonal context
Female physiology is cyclical in a way that male physiology is not, and Melanotan II's effects often vary across follicular versus luteal phase. Even where the compound's pharmacology is not directly hormonal, the cyclical hormone background influences how it is metabolised, distributed, and felt. Pre-menopausal users should expect to track response by cycle phase for one or two cycles before settling on a fixed schedule.
Perimenopause and menopause integration
For women in the perimenopausal or post-menopausal window, Melanotan II is most effective when integrated with the broader hormonal picture — HRT (estrogen, progesterone, sometimes testosterone), bone-density support, and cardiometabolic monitoring. Many compounds in this category produce stronger effects in this window precisely because the surrounding hormonal landscape is changing.
In the perimenopausal window, Melanotan II for cycle support produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.
Autoimmune Support is one of the dimensions on which women track Melanotan II response. Effect size depends on baseline hormonal status and on integration with HRT or contraception. Tracking by cycle phase for the first 1–2 cycles informs subsequent scheduling.
For bone density in female users, Melanotan II is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.
In the perimenopausal window, Melanotan II for endometriosis support produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 0.25-0.5 mg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 1.25-0.5 mg | 4–6 weeks initial cycle |
| Women's Health focus | SubQ | 0.25-0.5 mg | Daily during loading, then 1-2x weekly |
| Maintenance phase | SubQ | 1.25-0.5 mg | Ongoing with periodic pauses |
Dose timing for Melanotan II is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
Melanotan II stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from women's-health clinicians.
- Melanotan II + Oxytocin: Activates oxytocin receptors (OXTR) peripherally (uterine smooth muscle, mammary alveoli) and centrally (amygdala, hypothalamus, ventral tegmentum). Pairs naturally with Melanotan II's mechanism in female physiology protocols.
- Melanotan II + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with Melanotan II's mechanism in female physiology protocols.
- Melanotan II + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with Melanotan II's mechanism in female physiology protocols.
- Melanotan II + Epithalon: Identified by Khavinson in St. Pairs naturally with Melanotan II's mechanism in female physiology protocols.
Nausea (especially early), spontaneous erections in men, marked appetite suppression, hyperpigmentation. Watch new moles closely. Avoid in melanoma history.
Lens-specific safety considerations for female physiology use of Melanotan II: Nausea (especially early), spontaneous erections in men, marked appetite suppression, hyperpigmentation. Watch new moles closely. Avoid in melanoma history. Additional female physiology monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| Melanotan II | Cyclic α-MSH analogue | ~30 min | Women's Health |
| Oxytocin | Posterior pituitary nonapeptide | ~1-6 min plasma; CNS longer | The 'bonding hormone' — a posterior pituitary nonapeptide with effects on uterine contraction, lactation, and a wide range of social and sexual behaviour via central oxytocin receptors |
| Kisspeptin | Hypothalamic upstream regulator of GnRH | ~28 min IV | The upstream master regulator of GnRH neurons — driving the entire HPG axis from above |
| PT-141 | Melanocortin receptor agonist | ~2-3 hr | An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women |
How will Melanotan II interact with my cycle?
Is Melanotan II appropriate during perimenopause?
Can I use Melanotan II alongside HRT?
Does Melanotan II affect bone density?
What should I look for in Melanotan II sourcing and quality?
What is the standard dosing protocol for Melanotan II?
Start a Melanotan II Protocol
Alukard provides physician-supervised women's health protocols with GMP-certified Melanotan II and Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.
Get ProtocolQuick Facts
- Molecular weight
- 1024 Da
- Sequence length
- 7 aa
- Half-life
- ~30 min
- WADA
- Not on prohibited list
- FDA
- Unapproved
- Research
- Mechanistic + off-label
Stack Partners
All female physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Melanotan II unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Female Physiology Protocol for Melanotan II
Alukard provides physician-supervised women's health protocols with Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.
HIPAA Compliant · GMP Certified · Physician Supervised